Drug development continues to evolve. In the last 20 years, the industry has progressed from evidence-based drug development to more targeted precision medicines. But is the industry now ready to move into a new phase of drug development?
Our October Clinical Leader Live featured three executives from Janssen discussing their work in the immunology space and the company’s current approach to discovering new treatments. The discussion focused on why development efforts are changing, what the future holds, Janssen’s current pathway approach that has the potential to treat multiple immune-mediated diseases with one therapy, and what this approach may mean to the future of clinical trials. The discussion also covered what these advancements will mean to patients, prescribers, and approval agencies. This conversation featured Newman Yeilding, Head of Immunology Development, Terence Rooney, VP of Clinical Development – Immunology, and Lloyd Miller, VP, Immunodermatology Disease Area Leader.
In this segment, Newman Yeilding, Terence Rooney, and Lloyd Miller discuss the changes that have taken place in drug development and define the pathway approach being pursued at Janssen.